91 related articles for article (PubMed ID: 16327307)
21. White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study.
Peluso M; Airoldi L; Armelle M; Martone T; Coda R; Malaveille C; Giacomelli G; Terrone C; Casetta G; Vineis P
Cancer Epidemiol Biomarkers Prev; 1998 Apr; 7(4):341-6. PubMed ID: 9568791
[TBL] [Abstract][Full Text] [Related]
22. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
Brockmöller J; Cascorbi I; Kerb R; Roots I
Cancer Res; 1996 Sep; 56(17):3915-25. PubMed ID: 8752158
[TBL] [Abstract][Full Text] [Related]
23. NAT2 gene polymorphism in bladder cancer: a study from North India.
Mittal RD; Srivastava DS; Mandhani A
Int Braz J Urol; 2004; 30(4):279-85; discussion 285-8. PubMed ID: 15679955
[TBL] [Abstract][Full Text] [Related]
24. Differential interactions between GSTM1 and NAT2 genotypes on aromatic DNA adduct level and HPRT mutant frequency in lung cancer patients and population controls.
Hou SM; Fält S; Yang K; Nyberg F; Pershagen G; Hemminki K; Lambert B
Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):133-40. PubMed ID: 11219770
[TBL] [Abstract][Full Text] [Related]
25. N-acetyltransferase-2 and medical history in bladder cancer cases with a suspected occupational disease (BK 1301) in Germany.
Weistenhofer W; Blaszkewicz M; Bolt HM; Golka K
J Toxicol Environ Health A; 2008; 71(13-14):906-10. PubMed ID: 18569594
[TBL] [Abstract][Full Text] [Related]
26. N-acetyltransferase 2 gene polymorphism as a biomarker for susceptibility to bladder cancer in Bangladeshi population.
Hosen MB; Islam J; Salam MA; Islam MF; Hawlader MZ; Kabir Y
Asia Pac J Clin Oncol; 2015 Mar; 11(1):78-84. PubMed ID: 25376209
[TBL] [Abstract][Full Text] [Related]
27. Gender-specific effects of NAT2 and GSTM1 in bladder cancer.
Schnakenberg E; Lustig M; Breuer R; Werdin R; Hübotter R; Dreikorn K; Schloot W
Clin Genet; 2000 Apr; 57(4):270-7. PubMed ID: 10845567
[TBL] [Abstract][Full Text] [Related]
28. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in northern Italy.
Shen M; Hung RJ; Brennan P; Malaveille C; Donato F; Placidi D; Carta A; Hautefeuille A; Boffetta P; Porru S
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1234-40. PubMed ID: 14652287
[TBL] [Abstract][Full Text] [Related]
29. N-acetyltransferase 2 (NAT2) genotypes, cigarette smoking, and the risk of breast cancer.
Alberg AJ; Daudt A; Huang HY; Hoffman SC; Comstock GW; Helzlsouer KJ; Strickland PT; Bell DA
Cancer Detect Prev; 2004; 28(3):187-93. PubMed ID: 15225898
[TBL] [Abstract][Full Text] [Related]
30. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese.
Inatomi H; Katoh T; Kawamoto T; Matsumoto T
Int J Urol; 1999 Sep; 6(9):446-54. PubMed ID: 10510890
[TBL] [Abstract][Full Text] [Related]
31. A significantly joint effect between arsenic and occupational exposures and risk genotypes/diplotypes of CYP2E1, GSTO1 and GSTO2 on risk of urothelial carcinoma.
Wang YH; Yeh SD; Shen KH; Shen CH; Juang GD; Hsu LI; Chiou HY; Chen CJ
Toxicol Appl Pharmacol; 2009 Nov; 241(1):111-8. PubMed ID: 19686770
[TBL] [Abstract][Full Text] [Related]
32. N-Acetyltransferase 2 and glutathione s-transferase M1 in colon and rectal cancer cases from an industrialized area.
Golka K; Roemer HC; Weistenhöfer W; Blaszkewicz M; Hammad S; Reckwitz T; Loehlein D; Hartel M; Hengstler JG; Geller F
J Toxicol Environ Health A; 2012; 75(8-10):572-81. PubMed ID: 22686318
[TBL] [Abstract][Full Text] [Related]
33. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer.
Zhou W; Liu G; Thurston SW; Xu LL; Miller DP; Wain JC; Lynch TJ; Su L; Christiani DC
Cancer Epidemiol Biomarkers Prev; 2002 Jan; 11(1):15-21. PubMed ID: 11815396
[TBL] [Abstract][Full Text] [Related]
34. Meat intake and bladder cancer in a prospective study: a role for heterocyclic aromatic amines?
Lumbreras B; Garte S; Overvad K; Tjonneland A; Clavel-Chapelon F; Linseisen JP; Boeing H; Trichopoulou A; Palli D; Peluso M; Krogh V; Tumino R; Panico S; Bueno-De-Mesquita HB; Peeters PH; Lund E; Martinez C; Dorronsoro M; Barricarte A; Chirlaque MD; Quiros JR; Berglund G; Hallmans G; Day NE; Key TJ; Saracci R; Kaaks R; Malaveille C; Ferrari P; Boffetta P; Norat T; Riboli E; Gonzalez CA; Vineis P
Cancer Causes Control; 2008 Aug; 19(6):649-56. PubMed ID: 18264785
[TBL] [Abstract][Full Text] [Related]
35. Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers.
Salagovic J; Kalina I; Stubna J; Habalová V; Hrivnák M; Valanský L; Kohút A; Biros E
Neoplasma; 1998; 45(5):312-7. PubMed ID: 9921921
[TBL] [Abstract][Full Text] [Related]
36. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.
Hein DW; Doll MA; Fretland AJ; Leff MA; Webb SJ; Xiao GH; Devanaboyina US; Nangju NA; Feng Y
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):29-42. PubMed ID: 10667461
[TBL] [Abstract][Full Text] [Related]
37. Genotyping of the polymorphic N-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients.
Schnakenberg E; Ehlers C; Feyerabend W; Werdin R; Hübotter R; Dreikorn K; Schloot W
Clin Genet; 1998 May; 53(5):396-402. PubMed ID: 9660060
[TBL] [Abstract][Full Text] [Related]
38. Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk.
Chang-Claude J; Kropp S; Jäger B; Bartsch H; Risch A
Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):698-704. PubMed ID: 12163321
[TBL] [Abstract][Full Text] [Related]
39. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.
Hein DW
Oncogene; 2006 Mar; 25(11):1649-58. PubMed ID: 16550165
[TBL] [Abstract][Full Text] [Related]
40. N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort.
Pesch B; Gawrych K; Rabstein S; Weiss T; Casjens S; Rihs HP; Ding H; Angerer J; Illig T; Klopp N; Bueno-de-Mesquita B; Ros MM; Kaaks R; Chang-Claude J; Roswall N; Tjønneland A; Overvad K; Clavel-Chapelon F; Boutron-Ruault MC; Dossus L; Boeing H; Weikert S; Trichopoulos D; Palli D; Sieri S; Tumino R; Panico S; Quirós JR; González C; Sánchez MJ; Dorronsoro M; Navarro C; Barricarte A; Ljungberg B; Johansson M; Ulmert D; Ehrnström R; Khaw KT; Wareham N; Key TJ; Ferrari P; Romieu I; Riboli E; Brüning T; Vineis P
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2055-65. PubMed ID: 24092628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
